Magnesium orotate in severe congestive heart failure (MACH).

Abstract

BACKGROUND:

Aim of this study was to evaluate adjuvant magnesium orotate on mortality and clinical symptoms in patients with severe heart failure under optimal cardiovascular medication.

METHODS:

In a monocentric, controlled, double-blind study, 79 patients with severe congestive heart failure (NYHA IV) under optimal medical cardiovascular treatment were randomised to receive either magnesium orotate (6000 mg for 1 month, 3000 mg for about 11 months, n=40) or placebo (n=39). Both groups were comparable in demographic data, duration of heart failure and pre- and concomitant treatment.

RESULTS:

After mean treatment duration of 1 year (magnesium orotate: 364.1+/-14.7 days, placebo: 361.2+/-12.7 days) the survival rate was 75.7% compared to 51.6% under placebo (p<0.05). Clinical symptoms improved in 38.5% of patients under magnesium orotate, whereas they deteriorated in 56.3% of patients under placebo (p<0.001).

CONCLUSION:

Magnesium orotate may be used as adjuvant therapy in patients on optimal treatment for severe congestive heart failure, increasing survival rate and improving clinical symptoms and patient's quality of life.

• Authors: O B Stepura, A I Martynow
• Journal: International journal of cardiology (Int J Cardiol) Vol. 131 Issue 2 Pg. 293-5 (Jan 09 2009) ISSN: 1874-1754 [Electronic] Netherlands
• PMID: 18281113 (Publication Type: Comparative Study, Corrected and Republished Article, Letter, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Orotic Acid
• magnesium orotate

Topics

• Adult
• Aged
• Double-Blind Method
• Female
• Heart Failure (drug therapy, mortality, physiopathology)
• Humans
• Male
• Middle Aged
• Orotic Acid (analogs & derivatives, therapeutic use)
• Prospective Studies
• Survival Rate (trends)
• Young Adult